Detalhe da pesquisa
1.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
J Am Acad Dermatol
; 90(5): 986-993, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38253129
2.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38556093
3.
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
N Engl J Med
; 383(3): 229-239, 2020 07 16.
Artigo
Inglês
| MEDLINE | ID: mdl-32668113
4.
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Br J Dermatol
; 189(4): 392-399, 2023 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37279795
5.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
JAMA
; 328(11): 1073-1084, 2022 09 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36125472
6.
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
J Drugs Dermatol
; 19(8): 734-740, 2020 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32845114
7.
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Br J Dermatol
; 188(6): 810-812, 2023 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36890712
8.
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
J Am Acad Dermatol
; 78(6): 1156-1163, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29409914
9.
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
J Am Acad Dermatol
; 2018 Jan 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29409915
10.
Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study.
J Drugs Dermatol
; 17(3): 333-338, 2018 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29537451
11.
Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.
J Drugs Dermatol
; 17(3): 308-316, 2018 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29537449
12.
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
J Drugs Dermatol
; 17(6): 621-626, 2018 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29879249
13.
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
J Drugs Dermatol
; 17(3): 290-298, 2018 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29537447
14.
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
J Drugs Dermatol
; 17(1): 97-105, 2018 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29320594
15.
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
J Drugs Dermatol
; 17(9): 987-996, 2018 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30235387
16.
Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu.
J Drugs Dermatol
; 16(6): 591-598, 2017 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28686777
17.
Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.
J Drugs Dermatol
; 15(10): 1250-1259, 2016 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27741344
18.
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
J Drugs Dermatol
; 15(8): 962-9, 2016 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27537997
19.
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
J Drugs Dermatol
; 15(5): 553-61, 2016 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27168264
20.
Genomic profiling of a human organotypic model of AEC syndrome reveals ZNF750 as an essential downstream target of mutant TP63.
Am J Hum Genet
; 91(3): 435-43, 2012 Sep 07.
Artigo
Inglês
| MEDLINE | ID: mdl-22922031